Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Diagnostics Firm Nucleix Plans European Market Expansion

Executive Summary

Cancer diagnostics company Nucleix is planning to scale up commercial activities in Europe for its bladder test Bladder EpiCheck. The Israeli firm told Medtech Insight it is currently in advanced negotiations with distributors to expand the test's commercial reach.

You may also be interested in...



Nucleix Adds $55M To Support EpiCheck Lung Cancer Test

The new money will help the company advance its unique EpiCheck technology for detecting cancer-specific-changes to DNA called methylation.

Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.

Angle Files De Novo Submission For Parsortix System In Breast Cancer

The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.

Topics

UsernamePublicRestriction

Register

MT123034

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel